Search research articles
Contact Us
Filters
Showing results (231-240 of 288) with videos related to
Page
of 29
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
April 8, 2021
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort
Victor Moreno, Pilar Garrido, Kyriakos P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2017
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W Tolcher, Mario Sznol, Siwen Hu-Lieskovan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2012
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer
Toshio Shimizu, Anthony W Tolcher, Kyriakos P Papadopoulos, et al.
The Oncologist
|
March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Anthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
Journal of Environmental Radioactivity
|
November 3, 2022
Tritium and radiocarbon in the water column of the Red Sea
P P Povinec, V P Papadopoulos, G Krokos, et al.
Bone Marrow Transplantation
|
November 18, 1998
High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults
K P Papadopoulos, J H Garvin, M Fetell, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Jeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
Anthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.
British Journal of Cancer
|
October 4, 2017
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
K P Papadopoulos, B F El-Rayes, A W Tolcher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 21, 2014
A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours
Anthony Tolcher, Jonathan Goldman, Amita Patnaik, et al.
Page
of 29
Search research articles
Search
Showing results (231-240 of 288) with videos related to
Sort By:
Page
of 29
Lung Cancer (Amsterdam, Netherlands)
|
April 8, 2021
Tolerability and antitumor activity of cemiplimab, a human monoclonal anti-PD-1, as monotherapy in patients with pretreated non-small cell lung cancer (NSCLC): Data from the Phase 1 NSCLC expansion cohort
Victor Moreno, Pilar Garrido, Kyriakos P Papadopoulos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 22, 2017
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors
Anthony W Tolcher, Mario Sznol, Siwen Hu-Lieskovan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 21, 2012
The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer
Toshio Shimizu, Anthony W Tolcher, Kyriakos P Papadopoulos, et al.
The Oncologist
|
March 8, 2018
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Anthony Tolcher, Keith Flaherty, Geoffrey I Shapiro, et al.
Journal of Environmental Radioactivity
|
November 3, 2022
Tritium and radiocarbon in the water column of the Red Sea
P P Povinec, V P Papadopoulos, G Krokos, et al.
Bone Marrow Transplantation
|
November 18, 1998
High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults
K P Papadopoulos, J H Garvin, M Fetell, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 16, 2013
A phase 1b study of trametinib, an oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours
Jeffrey R Infante, Kyriakos P Papadopoulos, Johanna C Bendell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 15, 2016
A Phase I Dose-Escalation Study Evaluating the Safety Tolerability and Pharmacokinetics of CUDC-427, a Potent, Oral, Monovalent IAP Antagonist, in Patients with Refractory Solid Tumors
Anthony W Tolcher, Johanna C Bendell, Kyriakos P Papadopoulos, et al.
British Journal of Cancer
|
October 4, 2017
A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours
K P Papadopoulos, B F El-Rayes, A W Tolcher, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 21, 2014
A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours
Anthony Tolcher, Jonathan Goldman, Amita Patnaik, et al.
Page
of 29